Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[New strategies in cancer immunotherapy].

Ruan RS, Xu KC.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):943-6. Chinese. No abstract available.

PMID:
22340107
2.

Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.

Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S.

Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.

PMID:
18834631
3.

A new era for cancer immunotherapy based on the genes that encode cancer antigens.

Rosenberg SA.

Immunity. 1999 Mar;10(3):281-7. Review. No abstract available.

4.

Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?

Zöller M, Matzku S.

Arch Immunol Ther Exp (Warsz). 2002;50(3):197-224. Review.

PMID:
12098935
5.

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Knutson KL, Disis ML.

Cancer Immunol Immunother. 2005 Aug;54(8):721-8. Epub 2005 Jan 27. Review.

PMID:
16010587
6.

Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?

Fry TJ, Lankester AC.

Pediatr Clin North Am. 2008 Feb;55(1):147-67, xi. doi: 10.1016/j.pcl.2007.10.015. Review.

PMID:
18242319
7.

Cancer vaccines: the state of the art.

Finn OO, Banchereau J.

Semin Immunol. 2010 Jun;22(3):103-4. No abstract available.

PMID:
20552730
8.
9.

Dendritic cells as vectors for immunotherapy of cancer.

Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK.

Semin Cancer Biol. 2003 Dec;13(6):439-47. Review.

PMID:
15001163
10.

Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.

Neeson P, Paterson Y.

Immunol Invest. 2006;35(3-4):359-94. Review.

PMID:
16916758
11.

The critical role of type-1 innate and acquired immunity in tumor immunotherapy.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T.

Cancer Sci. 2004 Sep;95(9):697-703. Review.

12.

Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.

Zheng R, Kjaergaard J, Lee WT, Cohen PA, Shu S.

Cancer Treat Res. 2007;135:223-37. Review. No abstract available.

PMID:
17953420
13.

A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.

Nelson B.

Cancer Cytopathol. 2014 Jan;122(1):1-2. doi: 10.1002/cncy.21390. No abstract available.

14.

Cancer vaccines and immunotherapy.

Dermime S, Armstrong A, Hawkins RE, Stern PL.

Br Med Bull. 2002;62:149-62. Review.

PMID:
12176857
15.

Cancer immunotherapy: novel strategies and clinical experiences.

Schmitz M, Bornhäuser M, Ockert D, Rieber EP.

Trends Immunol. 2002 Sep;23(9):428-9. No abstract available.

PMID:
12200057
16.

[Oncoimmunology: some fundamental problems of cancer immunotherapy].

Nedospasov SA, Kuprash DV.

Mol Biol (Mosk). 2007 Mar-Apr;41(2):355-68. Review. Russian.

PMID:
17514902
17.

A new twist on autologous cancer vaccines.

Emens LA.

Cancer Biol Ther. 2003 Mar-Apr;2(2):161-3. No abstract available.

PMID:
12750555
18.
19.

Coupled for cross-presentation in tumor immunotherapy.

Pang B, Neefjes J.

Sci Transl Med. 2010 Aug 11;2(44):44ps40. doi: 10.1126/scitranslmed.3001245. Review.

PMID:
20702855
20.

Strategies for immune therapy: Würzburg, Germany, 29 February-3 March 2004.

Pawelec G, Gouttefangeas C.

Cancer Immunol Immunother. 2004 Aug;53(8):755-8. Epub 2004 May 4. No abstract available.

PMID:
15133632

Supplemental Content

Support Center